Tommy Fu Selected Research

MDS 004

11/2014

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tommy Fu Research Topics

Disease

3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2017 - 10/2013
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2014 - 10/2011
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018 - 12/2017
2	Multiple Myeloma 01/2010 - 07/2009
1	Lymphoma (Lymphomas) 12/2017
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/2017
1	Disease Progression 10/2013
1	Thromboembolism 01/2010
1	Venous Thromboembolism 01/2010
1	Chromosome Aberrations (Chromosome Abnormalities) 07/2009

Drug/Important Bio-Agent (IBA)

7	Lenalidomide (CC 5013)FDA Link 10/2017 - 07/2009
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2010 - 07/2009
1	MDS 004IBA 11/2014
1	Proteins (Proteins, Gene)FDA Link 06/2014
1	Bortezomib (Velcade)FDA Link 10/2013

Therapy/Procedure

4	Therapeutics 01/2018 - 07/2009
1	Stem Cell Transplantation 10/2013